Beobachtungsplan, NIS 522: “imPROve asthma” Change in measured Patient-Reported Outcomes in severe eosinophilic asthma patients treated with benralizumab under real-life conditions in Germany A prospective, 12-month, observational, multi-center study to investigate the change in patient-reported outcomes in severe eosinophilic asthma patients treated with benralizumab biologic therapy under real-life conditions in Germany

Datei

• Artikel "Beobachtungsplan, NIS 522: “imPROve asthma” Change in measured Patient-Reported Outcomes in severe eosinophilic asthma patients treated with benralizumab under real-life conditions in Germany A prospective, 12-month, observational, multi-center study to investigate the change in patient-reported outcomes in severe eosinophilic asthma patients treated with benralizumab biologic therapy under real-life conditions in Germany"Herunterladen(PDF, 2MB, Datei ist nicht barrierefrei)